Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by bfwon May 16, 2018 12:34pm

190 Views

Post# 28040005

RE:RE:RE:RE:RE:RE:RE:100 patients should be reach in few days

palinc2000 wrote: 80 cents EPS would be 1600 patients for a full year but the actual EPS in 12 months would probably be closer to 40-45 cents ......The multiple on trailing earmings would be over 80 to meet your TP but the multiple on forward earnings assuming an additional 1600 patients in the second year that would translate to 1.20 EPS and a multiple of 25

Good point.

bfw

Bullboard Posts

AI companies to invest in